CONGRESSIONAL BRIEFING: Preparing for PREP (Pre-Exposure Prophylaxis): A Prevention Pill for HIV/AIDS?
What if those most at risk for HIV could take a pill that would reduce the risk of infection? The experimental technique involves administering anti-HIV drugs before possible exposure to HIV in the hope that this medication will lower the chances of infection among those at high risk—a hypothesis currently being tested in ongoing clinical trials. These trials, currently being funded by the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), USAID, the Gates Foundation, and others, are taking place in Botswana, Brazil, Ecuador, Peru, South Africa, Thailand, and the United States. Initial results are expected within the next 12 to 18 months. This amfAR Congressional Briefing convened a panel of leading experts to discuss ongoing clinical studies focusing on safety considerations and ethical concerns; policy recommendations surrounding access, reimbursement, and distribution; lessons learned from PMTCT, PEP, and malaria chemoprophylaxis; and challenges for PrEP in community receptivity and adaptability.
When: December 4, 2008
Where: Dirksen Senate Office Building
• Susan Blumenthal, M.D., M.P.A.
Senior Policy and Medical Advisor, amfAR, The Foundation for AIDS Research. Former Deputy Assistant Secretary for Women’s Health, Former Assistant Surgeon General of the United States
• Kevin Robert Frost
Chief Executive Officer, amfAR, The Foundation for AIDS Research
• Robert Grant, M.D., M.P.A.
Protocol Chair, iPreX Clinical Study
The PrEP Concept and Clinical Trials
• Carl Dieffenbach, Ph.D.
Director, Division of AIDS, National Institute of Allergy and Infectious Diseases
Current and Future Directions for PrEP Research
• Thomas Coates, Ph.D.
Professor of Global AIDS Research, UCLA
PrEP May Cause a Revolution in HIV Prevention: How Do We Prepare?
• Richard Wolitski., Ph.D.
Acting Director, HIV/AIDS Prevention Division, CDC
Policy Implications of PrEP Implementation in United States
• Kevin Cranston, M.Div.
Director, HIV/AIDS Bureau, Massachusetts Department of Public Health
A State Perspective: Balancing the Ethical and Resource Issues Raised by PrEP